| Old Articles: <Older 6401-6410 Newer> |
|---|
 |
The Motley Fool
June 17, 2010
Brian Orelli |
Merck Needs to Get Busy While waiting for the FDA to approve the expanded age range, sales of Merck's Gardasil have gone to sleep.   |
The Motley Fool
June 17, 2010
Claire Stephanic |
More Recall Troubles for Johnson & Johnson Its McNeil Consumer Healthcare division expands its recall on Tylenol and Motrin products. |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
The Motley Fool
June 16, 2010
Ryan McBride |
Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors. |
The Motley Fool
June 16, 2010
Brian Orelli |
Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products. |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
The Motley Fool
June 15, 2010
Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
The Motley Fool
June 15, 2010
Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. |
The Motley Fool
June 15, 2010
Ryan McBride |
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week. |
The Motley Fool
June 15, 2010
Rogers Weed |
Invest in Biotech, or Watch the U.S. Health Innovation Edge Slip Away Medical innovation is an industry where our country should shine brightest -- if we invest in it, that is. Battelle found that life-sciences leaders around the country are concerned that the United States is losing its edge. |
| <Older 6401-6410 Newer> Return to current articles. |
